PDS Biotechnology Co. (NASDAQ:PDSB) Receives Consensus Recommendation of “Buy” from Analysts

PDS Biotechnology Co. (NASDAQ:PDSB) has earned a consensus rating of “Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $14.25.

Several analysts have recently weighed in on the stock. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday, October 2nd. Finally, B. Riley decreased their price target on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th.

PDS Biotechnology Stock Performance

NASDAQ PDSB opened at $3.56 on Wednesday. The firm has a market cap of $130.58 million, a price-to-earnings ratio of -2.62 and a beta of 1.90. The company has a 50 day moving average of $3.24 and a 200-day moving average of $3.32. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a 1-year low of $2.53 and a 1-year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the business posted ($0.37) EPS. On average, equities analysts forecast that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Inspirion Wealth Advisors LLC raised its holdings in shares of PDS Biotechnology by 5.5% during the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock worth $1,406,000 after acquiring an additional 18,383 shares during the period. Kathleen S. Wright Associates Inc. bought a new stake in shares of PDS Biotechnology during the 1st quarter worth about $28,000. Vanguard Group Inc. boosted its holdings in shares of PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares during the period. Tempus Wealth Planning LLC bought a new stake in shares of PDS Biotechnology during the 2nd quarter worth about $55,000. Finally, Ground Swell Capital LLC bought a new stake in PDS Biotechnology in the 2nd quarter valued at about $67,000. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.